ArticleLa Radiologia medica2025
Evaluation of contrast-enhanced mammography (CEM) in the preoperative staging of breast cancer: large-scale single center experience, update to 1005 cases.
Article in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Early, delayed, or combined contrast-enhanced mammography for detecting residual disease after neoadjuvant chemotherapy in breast cancer.European radiology · 2026Article
- How to optimise breast cancer staging with contrast-enhanced mammography: current evidence and clinical implications.Insights into imaging · 2026Review
- Contrast-enhanced mammography in the preoperative assessment of primary operable breast cancer: Results from a prospective, two-centre study.European journal of radiology open · 2026Article
- Achieving single-contrast administration for enhanced chest CT and contrast-enhanced spectral mammography without compromising diagnostic quality: a comparative study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Contrast-Enhanced Mammography in Breast Lesion Assessment: Accuracy and Surgical Impact.Tomography (Ann Arbor, Mich.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to assess the diagnostic performance of CEM in the preoperative staging of breast cancer in a large cohort of patients. MATERIALS AND
methodsA retrospective review of preoperative staging CEM exams was conducted at our centre between June 2016 and June 2021. We evaluated cases where CEM influenced the type of surgery, necessitated additional biopsies or imaging, and identified additional lesions. The sensitivity, specificity, positive and negative predictive values (PPV and NPV), and accuracy of CEM for the entire sample and each subgroup setting were calculated. A receiver operating characteristic (ROC) curve and multivariate analysis were performed.
results991 women, mean age 61.3 years old [35-93], with 1005 malignant lesions were included. CEM led to additional imaging in 36.7% (364/991) women and to additional biopsies in 18.5% (183/991) women. CEM altered the initial surgical plan based on conventional imaging in 226 out of 991 patients (22.8%). CEM had a sensitivity in the whole population of 91.5% (204/223), specificity of 96.8% (757/782), PPV of 89.1% (204/229), NPV of 97.5% (757/776) and an accuracy of 95.6% (961/1005); the AUC of the ROC curve was 0.941. We found CEM better performed in patients with a low BPE level compared with a high BPE level (ρ = 0.028861). We see that the presence of additional lesions at CEM was the only significant predictor in the model.
conclusionThis study reaffirms the high diagnostic accuracy of CEM for preoperative breast cancer staging in a large patient cohort.
Indexed as
Identifiers
40153207What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.